Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

NCT02588651 is registered in ClinicalTrials.gov with Deepa Jagadeesh as lead sponsor.

NCT NCT02588651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02588651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Lead sponsor
Deepa Jagadeesh
Phase
Phase 2
Overall status
Completed
Start date
June 17, 2016
Completion date
October 14, 2024
Enrollment
23 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

adult t-cell leukemia/lymphoma, angioimmunoblastic t-cell lymphoma, enteropathy associated t-cell lymphoma, hepato-splenic t-cell lymphoma, nk t-cell lymphoma, t-cell lymphoma